OMB#: 0925-0766, Exp., 04/2023
Burden Disclosure Statement: Public reporting burden for this collection of information is estimated to average 5 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0648) Do not return the completed form to this address
1. Is this your first time participating in a review meeting for NIH (not including service as a mail reviewer)?
No
Yes
Don't know
2. Was your Fall 2022 review meeting held virtually or face-to-face?
Virtually
Face-to-face
Face-to face but I attended virtually
3. Please select how much you agree or disagree with the following statements.
|
Strongly agree |
Agree |
Somewhat agree |
Neutral |
Somewhat disagree |
Disagree |
Strongly disagree |
The panel was able to prioritize applications according to their impact and scientific merit. |
|
|
|
|
|
|
|
The scientific discussion helped the panel evaluate the applications being reviewed. |
|
|
|
|
|
|
|
4. Please rate your recent review meeting on the following items.
|
Excellent |
Good |
Fair |
Poor |
Very poor |
Don't know/Not applicable |
Overall quality of review |
|
|
|
|
|
|
Productivity of discussions |
|
|
|
|
|
|
Level of reviewer engagement |
|
|
|
|
|
|
Meeting management |
|
|
|
|
|
|
5. Please rate your recent review meeting on the following items.
|
Always or very frequently |
Often |
Sometimes |
Rarely |
Never |
Don't know/Not applicable |
I contributed to the discussion. |
|
|
|
|
|
|
I felt confident voicing my opinions. |
|
|
|
|
|
|
I felt others were receptive and responsive to my feedback. |
|
|
|
|
|
|
I was able to clearly communicate my opinions. |
|
|
|
|
|
|
I felt comfortable voting outside the range. |
|
|
|
|
|
|
6. Rate your attention span at the review meeting from 1-10, with 1 being really struggled to concentrate and 10 being no problem concentrating at all.
|
1 |
2 |
3 |
4 |
5 |
6 |
6 |
7 |
8 |
9 |
10 |
. |
|
7. Did you experience any technical difficulties with your virtual review meeting (e.g. audio, visual, connecting)?
Yes
No
Don't know
8. Assuming no or minimal health risks from COVID-19, would you be more likely to participate in a review meeting if it was held face-to-face or over video/Zoom?
Face-to-face
Video/Zoom
No preference
9. Approximately how many review meetings have you participated in for NIH?
|
0 |
1 |
2-5 |
6-15 |
16+ |
Face-to-face meetings |
|
|
|
|
|
Virtual meetings |
|
|
|
|
|
10. What stage of your career are you in?
Assistant Professor
Associate Professor
Professor
Other
11. What is your sex?
Male
Female
I prefer not to respond
12. Are you Hispanic or Latino?
Yes
No
I prefer not to respond
13. Which racial group(s) do you primarily identify as? Select all that apply.
American Indian or Alaska Native
Asian
Black or African-American
Native Hawaiian or other Pacific Islander
White
I prefer not to respond
14. In which U.S. time zone do you live?
Eastern Time (ET)
Central Time (CT)
Mountain Time (MT)
Pacific Time (PT)
Alaska Time (AT)
Hawaii-Aleutian Time (HAT)
Other U.S. time zone
I do not live in a U.S. time zone
15. Please share any comments (positive or negative) about your experience or general thoughts on your recent review meeting.
________________________________________________________________
________________________________________________________________
________________________________________________________________
Page
File Type | application/vnd.openxmlformats-officedocument.wordprocessingml.document |
File Title | Zoom 3 test |
Author | Qualtrics |
File Modified | 0000-00-00 |
File Created | 2023-08-30 |